Stifel Nicolaus reissued their buy rating on shares of Shire PLC (NASDAQ:SHPG) in a research report report published on Sunday morning. They currently have a $245.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on the company. Zacks Investment Research downgraded Shire PLC from a hold rating to a sell rating in a research report on Monday, July 17th. BidaskClub downgraded Shire PLC from a hold rating to a sell rating in a research report on Saturday, July 1st. ValuEngine downgraded Shire PLC from a buy rating to a hold rating in a research report on Friday, September 1st. Cantor Fitzgerald restated a buy rating and issued a $222.00 target price on shares of Shire PLC in a research report on Thursday, September 14th. Finally, BTIG Research restated a buy rating and issued a $242.00 target price on shares of Shire PLC in a research report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and thirteen have given a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $220.91.

Shire PLC (SHPG) opened at 151.09 on Friday. Shire PLC has a 52-week low of $139.36 and a 52-week high of $198.58.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Equities research analysts expect that Shire PLC will post $14.93 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/09/shire-plc-shpg-given-buy-rating-at-stifel-nicolaus.html.

The business also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be paid a dividend of $0.1527 per share. The ex-dividend date is Thursday, September 7th. This represents a yield of 0.21%. Shire PLC’s payout ratio is 41.07%.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Inspirion Wealth Advisors LLC grew its stake in Shire PLC by 0.4% during the 2nd quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 8 shares in the last quarter. Synovus Financial Corp grew its stake in Shire PLC by 0.4% during the 2nd quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 11 shares in the last quarter. Level Four Advisory Services LLC grew its stake in Shire PLC by 0.5% during the 1st quarter. Level Four Advisory Services LLC now owns 2,745 shares of the biopharmaceutical company’s stock worth $480,000 after purchasing an additional 13 shares in the last quarter. Baldwin Investment Management LLC grew its stake in Shire PLC by 1.4% during the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 23 shares in the last quarter. Finally, Hartford Financial Management Inc. grew its stake in Shire PLC by 5.4% during the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 32 shares in the last quarter. 19.28% of the stock is owned by hedge funds and other institutional investors.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.